BioSpace News Archive

Kaléo today announced that the U.S. Food and Drug Administration (FDA) has approved its Naloxone Auto-injector 10 mg (NALOXONE HYDROCHLORIDE injection) indicated for the emergency treatment of people 12 years of age and older where use of high-potency opioids such as fentanyl analogues as a chemical weapon, is suspected.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Cowen 42nd Annual Health Care Conference.

Genprex, Inc. today announced that the first patient was dosed in the Acclaim-1 clinical trial, an open-label, multi-center Phase 1/2 clinical trial evaluating the Company’s lead drug candidate, REQORSA™ Immunogene Therapy,

Aytu BioPharma, Inc. today announced that the European Commission granted orphan designation to AR101 (enzastaurin), a PKC inhibitor, for the treatment of Ehlers-Danlos Syndrome (EDS).

Graphite Bio, Inc. today announced the appointment of Alethia Young as chief financial officer.

IVERIC bio, Inc. reported that on March 1, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to four newly-hired, non-executive employees.

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the 42nd Annual Cowen Healthcare Conference being held virtually on Wednesday, March 9.

Stella Diagnostics Designated as a Semi-Finalist for SAGES Shark Tank 2022.

Thermo Fisher Scientific’s PPD clinical research business has been named a winner in Training magazine’s 2022 Training APEX Awards, recognizing its robust enterprise learning programs designed to grow employees’ skills and drive customers’ success.

Recursion announced its participation in the following upcoming investor conferences.